Jenrin Discovery is a privately-held emerging pharmaceutical company developing a pipeline of proprietary ‘first-in-class’ small molecule drugs designed to selectively target peripheral tissues. Many marketed drugs that are not dependent on brain penetration are plagued by a sub-optimal safety profile, due to psychiatric and neurologic side effects. Jenrin applies its medicinal chemistry expertise to structurally modify such agents so as to prevent penetration across the blood-brain barrier, resulting in negligible or no brain levels of compound. The new peripherally selective (PS) chemical entities retain the pharmacological activity and druggable properties of the parent therapeutic with little or no risk of the neuropsychiatric liabilities that accompanied the original agents. The Jenrin strategy of ‘rational drug re-design’ capitalizes on the years of medicinal chemistry that optimized the pharmacodynamic and PK properties of the original drug, significantly shortening discovery timelines and lowering development risk of the new proprietary agents.
Development activities have focused on potential therapeutics for chronic diseases including diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders and malaria. More than a dozen patent applications have been filed, and more than 1,200 compounds have been synthesized in these programs. Jenrin is seeking a strategic collaboration for its most advanced program, CB1-receptor blockade, targeting diabetes, liver diseases, and obesity.